DETAILED DESCRIPTION The invention claimed is: 1.
A polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 4, or an amide, ester or salt thereof.
2.
The polypeptide according to claim 1 consisting of the amino acid sequence as shown in SEQ ID NO: 4, or an amide, ester or salt thereof.
3.
A method for producing the polypeptide according to claim 1 or an amide, ester or salt thereof, comprising culturing a transformant transformed with a recombinant vector comprising a polynucleotide having a nucleotide sequence encoding the polypeptide according to claim 1; and allowing the polypeptide according to claim 1 to be produced and accumulated.
4.
A method for screening for compounds, or salts thereof, that promote or inhibit the activity of the polypeptide according to claim 1 or an amide, ester or salt thereof, wherein the method is characterized by using the polypeptide according to claim 1 or an amide, ester or salt thereof.
5.
A kit for screening for compounds, or salts thereof, that promote or inhibit the activity of the polypeptide according to claim 1 or an amide, ester or salt thereof, which comprises the polypeptide according to claim 1 or an amide, ester or salt thereof.
6.
A medicine comprising the polypeptide according to claim 1 or an amide, ester or salt thereof.
7.
The medicine according to claim 6, wherein said medicine is a prophylactic and/or therapeutic agent for neurodegenerative disorders or brain dysfunctions.
8.
The medicine according to claim 7, wherein said medicine is a prophylactic and/or therapeutic agent for Alzheimer's disease, Parkinson's disease, Down syndrome, amyotrophic lateral sclerosis, prion disease, Creutzfeldt-Jacob disease, Huntington's chorea, diabetic neuropathy, multiple sclerosis, brain infarction, cerebral hemorrhage, subarachnoid hemorrhage, ischemic brain diseases, epidural hematoma or subdural hematoma.
9.
The medicine according to claim 7, wherein said medicine is a prophylactic and/or therapeutic agent for Alzheimer's disease
|
Gene Therapy 
